Results 181 to 190 of about 73,102 (302)

Cellular signal-responsive m⁵C editing by an inducible split CRISPR platform. [PDF]

RNA
Dong C, Xu Y, Wu K, Mu N, Kumar S, Liang FS.   +5 more
europepmc   +1 more source

KAT8‐Low Osteosarcoma Suppresses Cisplatin Sensitivity via H4K16ac‐Mediated Cell Apoptosis

Med Research, EarlyView.
The scientific significance of this study is highlighted below: (1) Data mining and clinical discovery: These findings establish a direct clinical link between the KAT8–H4K16ac axis and chemotherapy response in osteosarcoma. (2) Multi‐omics and machine‐learning integration: We integrated proteomics and CUT&Tag multi‐omics to elucidate how chromatin ...
Zhenqun Zhao, Guohui Yu, Shikui Wu, Zhiyang Zhang, Keke Wang, Yingxin Xiong, Chao Sun, Haobo Cui, Yuxing Wang, Ziheng Wang, Huiru Zhang, Huiqin Xue, Shibing Guo   +12 more
wiley   +1 more source

Reductant-Responsive Squalene Dual-Prodrug Nanoparticles Co-Delivering Doxorubicin and Exatecan for Synergistic Breast Tumor Therapy. [PDF]

Pharmaceutics
Wang L, Yang N, Sa Y, Li Z, Qiao Y, Yang Y, Chen L, Liu X, Li L.   +8 more
europepmc   +1 more source

Protein Glutamylation: From Cytoskeleton to Signaling

Med Research, EarlyView.
Tubulin glutamylation, γ‐glutamylation, and nontubulin glutamylation are distinct yet interconnected post‐translational modifications that regulate diverse physiological and pathological processes, including cytoskeletal organization, cell cycle progression, immunity, metabolism, and disease development.
Jiayuan Chen, Yi Yuan, Qingquan Yu, Xinyue Wang, Hui Wang   +4 more
wiley   +1 more source

Oral nano-delivery of a gut microbial metabolite enhances T cell stemness for cancer immunotherapy. [PDF]

Nat Nanotechnol
Han K, Cho YS, Takahashi M, Zhou X, Dobson HE, Hutchings K, Wu Y, Na Y, Xie F, Crowther J, Wu J, Xu J, Lee C, Jasewicz H, Kim Y, Nenwani M, Animasahun O, Wuchu F, Andren A, Wong H, Camp E, Wan Z, Wu Q, Zhang L, Xu C, Dong K, Xu Y, Schwendeman A, Chen GY, Xie Y, Lyssiotis CA, Clasby M, Nagrath D, Lei YL, Moon JJ.   +34 more
europepmc   +1 more source

Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies

Medicinal Research Reviews, EarlyView.
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva, Alessandra Aiello, Tonino Alonzi, M. Alice Carvalho, Vladimir Finger, Delia Goletti, Sven Hoffner, Yousra Kherabi, Jan Korabecny, Julia Kulczyńska, Agnieszka Kyzioł, Alicia Lacoma, Filomena Martins, Zorica Nanovic, Sepideh Hosseiniporgham, Martina Hrast Rambaher, Leonardo Antonio Sechi, Daria Smalchuk, Grażyna Stochel, Lydia Tabernero, Nancy L. Tateosian, Violeta Valcheva, Anamarija Zega, Mafalda Sarraguça   +23 more
wiley   +1 more source

The Development of Four-Arm PEG-Based Thermoresponsive Dexamethasone Prodrugs for the Treatment of Osteoarthritis Pain. [PDF]

Nanomaterials (Basel)
Deng Y, Arash S, Rong J, Althobaiti SA, Liu S, Ransdell-Green E, Fehringer EV, Wang D.   +7 more
europepmc   +1 more source

Boronic Acid Inhibitors of β‐Lactamases: A Promising Strategy Against Antimicrobial Resistance

Medicinal Research Reviews, EarlyView.
ABSTRACT The rise of antimicrobial resistance (AMR) poses a critical threat to global health, mostly due to the proliferation of β‐lactamases, a class of enzymes responsible for the inactivation of β‐lactam antibiotics. Among the most promising strategies to restore β‐lactam efficacy is the use of β‐lactamase inhibitors (BLIs), with boronic acid ...
Nicolò Santi, Federico Corsini, Robert A. Bonomo, Emilia Caselli, Fabio Prati   +4 more
wiley   +1 more source

Cathepsin Family Proteases in Prodrug Design: Recent Advances. [PDF]

ChemMedChem
Liu H, Zheng M, Ng CS, Loh TP.
europepmc   +1 more source

AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma

Medicinal Research Reviews, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo, Kaeun Chae, Jueun Lee, Inseon Kim, Seunghun S. Lee   +4 more
wiley   +1 more source